Skin toxicity during first-line enfortumab vedotin-pembrolizumab linked to treatment outcomes in single-center cohort

Retrospective · JAMA Netw Open · 2026-10-21. Number 5 in the UrologyWatch Top 5 for October 21, 2026.

Among 185 patients with advanced urothelial carcinoma receiving first-line enfortumab vedotin plus pembrolizumab, over half developed treatment-emergent skin toxicity (rash or pruritus), most commonly within two weeks of starting therapy.

Why it matters: Single-center retrospective data raise the question of whether early skin toxicity tracks with outcomes on enfortumab vedotin-pembrolizumab, warranting prospective validation.

Limitation: Single-center retrospective cohort; findings on the toxicity-outcome association may not generalize and causal direction cannot be established.

Source: JAMA Netw Open · PubMed 42900474 · DOI 10.1001/jamanetworkopen.2026.39517

The full October 21, 2026 edition · Today's urology news